TY - JOUR
T1 - Anti-Galectin-2 Antibody Treatment Reduces Atherosclerotic Plaque Size and Alters Macrophage Polarity
AU - Kane, Jamie
AU - Jansen, Matthijs
AU - Hendrix, Sebastian
AU - Bosmans, Laura A.
AU - Beckers, Linda
AU - Tiel, Claudia Van
AU - Gijbels, Marion
AU - Zelcer, Noam
AU - Vries, Carlie J. De
AU - von Hundelshausen, Philipp
AU - Vervloet, Marc
AU - Eringa, Ed
AU - Horrevoets, Anton J.
AU - Royen, Niels Van
AU - Lutgens, Esther
N1 - Funding Information: This project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Actions, grant agreement No. 812699 (to J.K.). We also acknowledge the support from Amsterdam Cardiovascular Sciences for grant support (to M.J.), as well as the Netherlands Cardiovascular Research Initiative: the Dutch Heart Foundation, Dutch Federation of University Medical Centres, the Netherlands Organization for Health Research, and Development and the Royal Netherlands Academy of Sciences for the GENIUS-II project ‘Generating the best evidence-based pharmaceutical targets for atherosclerosis’ (CVON2017–22 to E.L.). This study was also supported by the Deutsche Forschungsgemein-schaft (CRC 1123 to E.L., P.v.H.). Publisher Copyright: © 2022 Georg Thieme Verlag. All rights reserved.
PY - 2022/6/1
Y1 - 2022/6/1
N2 - Background Galectins have numerous cellular functions in immunity and inflammation. Short-term galectin-2 (Gal-2) blockade in ischemia-induced arteriogenesis shifts macrophages to an anti-inflammatory phenotype and improves perfusion. Gal-2 may also affect other macrophage-related cardiovascular diseases. Objectives This study aims to elucidate the effects of Gal-2 inhibition in atherosclerosis. Methods ApoE -/-mice were given a high-cholesterol diet (HCD) for 12 weeks. After 6 weeks of HCD, intermediate atherosclerotic plaques were present. To study the effects of anti-Gal-2 nanobody treatment on the progression of existing atherosclerosis, treatment with two llama-derived anti-Gal-2 nanobodies (clones 2H8 and 2C10), or vehicle was given for the remaining 6 weeks. Results Gal-2 inhibition reduced the progression of existing atherosclerosis. Atherosclerotic plaque area in the aortic root was decreased, especially so in mice treated with 2C10 nanobodies. This clone showed reduced atherosclerosis severity as reflected by a decrease in fibrous cap atheromas in addition to decreases in plaque size. The number of plaque resident macrophages was unchanged; however, there was a significant increase in the fraction of CD206 +macrophages. 2C10 treatment also increased plaque α-smooth muscle content, and Gal-2 may have a role in modulating the inflammatory status of smooth muscle cells. Remarkably, both treatments reduced serum cholesterol concentrations including reductions in very low-density lipoprotein, low-density lipoprotein, and high-density lipoprotein while triglyceride concentrations were unchanged. Conclusion Prolonged and frequent treatment with anti-Gal-2 nanobodies reduced plaque size, slowed plaque progression, and modified the phenotype of plaque macrophages toward an anti-inflammatory profile. These results hold promise for future macrophage modulating therapeutic interventions that promote arteriogenesis and reduce atherosclerosis.
AB - Background Galectins have numerous cellular functions in immunity and inflammation. Short-term galectin-2 (Gal-2) blockade in ischemia-induced arteriogenesis shifts macrophages to an anti-inflammatory phenotype and improves perfusion. Gal-2 may also affect other macrophage-related cardiovascular diseases. Objectives This study aims to elucidate the effects of Gal-2 inhibition in atherosclerosis. Methods ApoE -/-mice were given a high-cholesterol diet (HCD) for 12 weeks. After 6 weeks of HCD, intermediate atherosclerotic plaques were present. To study the effects of anti-Gal-2 nanobody treatment on the progression of existing atherosclerosis, treatment with two llama-derived anti-Gal-2 nanobodies (clones 2H8 and 2C10), or vehicle was given for the remaining 6 weeks. Results Gal-2 inhibition reduced the progression of existing atherosclerosis. Atherosclerotic plaque area in the aortic root was decreased, especially so in mice treated with 2C10 nanobodies. This clone showed reduced atherosclerosis severity as reflected by a decrease in fibrous cap atheromas in addition to decreases in plaque size. The number of plaque resident macrophages was unchanged; however, there was a significant increase in the fraction of CD206 +macrophages. 2C10 treatment also increased plaque α-smooth muscle content, and Gal-2 may have a role in modulating the inflammatory status of smooth muscle cells. Remarkably, both treatments reduced serum cholesterol concentrations including reductions in very low-density lipoprotein, low-density lipoprotein, and high-density lipoprotein while triglyceride concentrations were unchanged. Conclusion Prolonged and frequent treatment with anti-Gal-2 nanobodies reduced plaque size, slowed plaque progression, and modified the phenotype of plaque macrophages toward an anti-inflammatory profile. These results hold promise for future macrophage modulating therapeutic interventions that promote arteriogenesis and reduce atherosclerosis.
KW - anti-inflammatory agents
KW - atherosclerosis
KW - galectin-2
KW - macrophages
KW - nanobodies
UR - http://www.scopus.com/inward/record.url?scp=85124825226&partnerID=8YFLogxK
U2 - https://doi.org/10.1055/a-1711-1055
DO - https://doi.org/10.1055/a-1711-1055
M3 - Article
C2 - 34852377
SN - 0340-6245
VL - 122
SP - 1047
EP - 1057
JO - Thrombosis and haemostasis
JF - Thrombosis and haemostasis
IS - 6
ER -